Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 701–800 of 1,000
Albert, S. G., & Wood, E. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.06.015 · Cited by 12
Zheng, J., van Schaick, E., Wu, L. S., Jacqmin, P., & Ruixo, J. J. P. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9422-4 · Cited by 11
Osteopenia and osteoporosis in HIV: pathogenesis and treatment
Chew, N., Doran, P., & Powderly, W. G. (2007) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3281a3c092 · Cited by 11
Denosumab for the Management of Postmenopausal Osteoporosis
Singer, A. J., & Grauer, A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2235 · Cited by 11
Disease Progression Analysis: Towards Mechanism-Based Models
Schmidt, S., Post, T. M., Boroujerdi, M. A., van Kesteren, C., Ploeger, B. A., Pasqua, O. E. D., & Danhof, M. (2010) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4419-7415-0_19 · Cited by 11
Clarke, B. L. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79335-7 · Cited by 13
Hormone-refractory prostate cancer: choosing the appropriate treatment option.
Ross, R. W., & Kantoff, P. W. (2007) · PubMed · Cited by 11
Kinoshita, H., Orita, S., Yonemoto, T., Ishii, T., Iwata, S., Kamoda, H., Tsukanishi, T., Inage, K., Abe, K., Inoue, M., et al. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2029-4 · Cited by 11
Lane, N. E. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32816a9436 · Cited by 12
Fan, T., Zhang, & Sen, S. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s39076 · Cited by 11
TNF Conference 2009: Beyond Bones – RANKL/RANK in the Immune System
Leibbrandt, A., & Penninger, J. M. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6612-4_2 · Cited by 11
Denosumab increases spine bone density in women with anorexia nervosa: a randomized clinical trial
Haines, M. S., Kimball, A., Meenaghan, E. M., Santoso, K., Colling, C., Singhal, V., Ebrahimi, S., Gleysteen, S., Schneider, M., Ciotti, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0248 · Cited by 10
Wright, N. C., Curtis, J. R., Arora, T., Smith, W. K., Kilgore, M. L., Saag, K. G., Safford, M. M., & Delzell, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131601 · Cited by 10
Good clinical endpoints with denosumab in osteoporosis and cancer
Doggrell, S. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903365197 · Cited by 10
Burns, R. B., Rosen, H. N., Berry, S. D., & Smetana, G. W. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0950 · Cited by 10
Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R., Nasu, Y., & Okazaki, K. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1812793 · Cited by 10
Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review
Xu, J., Li, H., Qu, Y., Zheng, C. R., Wang, B., Shen, P., Xie, Z., Wei, K., Wang, Y., & Zhao, J. (2021) · Arthroplasty · doi:10.1186/s42836-021-00068-6 · Cited by 10
Lewiecki, E. M., Anderson, P. A., Bilezikian, J. P., Binkley, N., Cheung, A. M., Imel, E. A., Krueger, D. C., McClung, M. R., Miller, P. D., & Rothman, M. S. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.10.001 · Cited by 11
Self-citationNihashi, Y., Miyoshi, M., Umezawa, K., Shimosato, T., & Takaya, T. (2022) · Nanomaterials · doi:10.3390/nano12101680 · Cited by 11
The efficacy of denosumab in Korean male patients with osteoporosis
Jeong, C., Ha, J., Kim, J., Lim, Y., Kim, M. K., Kwon, H.-S., Song, K., Kang, M. I., & Baek, K. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.064 · Cited by 10
Chapter 34. Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., & Delmas, P. D. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch34 · Cited by 10
NFAT Signaling and Bone Homeostasis
Chen, S. (2013) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000102 · Cited by 12
Kobel, C., Frey, D., Graf, N., Wuthrich, R. P., & Bonani, M. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000503066 · Cited by 10
Effects of Denosumab on Bone Turnover Markers in Postmenopausal Osteoporosis
Clarke, B. L. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.04.001 · Cited by 10
Osteocytes Specific GSK3 Inhibition Affects In Vitro Osteogenic Differentiation
Bertacchini, J., Magarò, M. S., Potì, F., & Palumbo, C. (2018) · Biomedicines · doi:10.3390/biomedicines6020061 · Cited by 11
The Intimidation of American Physicians — Banning Partial-Birth Abortion
Greene, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078084 · Cited by 10
The Heart of Drug Discovery and Development: Rational Target Selection
Spector, R., & Vesell, E. S. (2006) · Pharmacology · doi:10.1159/000093166 · Cited by 10
Gasser, J. A. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.004 · Cited by 11
The p53-miR17 family-Rankl axis bridges liver-bone communication
Ma, G., Cheng, S., Han, Y., Tang, W., Pang, W., Chen, L., Ding, Z., & Cao, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.046 · Cited by 10
Current and emerging bone resorption inhibitors for the treatment of osteoporosis
Gogakos, A. I., & Anastasilakis, A. D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451741 · Cited by 9
RANK/RANKL Signaling Pathway in Breast Development and Cancer
Pérez-Chacón, G., Santamaría, P. G., Redondo-Pedraza, J., & González‐Suárez, E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_16 · Cited by 10
Drug-induced regeneration of pancreatic beta cells: An approach to cellular therapeutic targets
Parsi, P., Saharkhiz, S., Farani, M. R., Bakhtiyari, S., & Alipourfard, I. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00255-9 · Cited by 9
Mei, L., Zheng, Y., Ma, T., Xia, B., Gao, X. J., Hao, Y., Luo, Z., & Huang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.734774 · Cited by 11
Wu, X.-P., Zhang, H., Xie, H., Luo, X., Peng, Y., Yuan, L., Dai, R.-C., Sheng, Z., Wu, X., & Liao, E.-Y. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2439-x · Cited by 9
Prevalent and Emerging Therapies for Osteoporosis
Brar, K. (2010) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(10)80050-4 · Cited by 10
Therapeutic Options for Low Bone Mineral Density in HIV-Infected Subjects
Cotter, A. G., & Mallon, P. W. G. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-012-0117-9 · Cited by 10
O’Connell, M. B. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.s6-a.s10 · Cited by 9
Collins, M. T., Riminucci, M., & Bianco, P. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch94 · Cited by 9
Wu, J., Wang, C., Li, G., Tang, E., & Zheng, Q. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14487 · Cited by 9
Rosenberg, D., Avni, T., Tsvetov, G., Gafter‐Gvili, A., & Diker‐Cohen, T. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05704-6 · Cited by 9
Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease
Adhikari, M., & Delgado‐Calle, J. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00679-7 · Cited by 10
Catton, B., Surangiwala, S., & Towheed, T. (2021) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14101 · Cited by 10
Esser‐Skala, W., Wohlschlager, T., Regl, C., & Huber, C. G. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202002147 · Cited by 9
Evaluation and Management of Elevated Parathyroid Hormone Levels in Normocalcemic Patients
Cusano, N. E. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.017 · Cited by 9
Bisphosphonate Mechanisms of Action
Reszka, A. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-459-9_19 · Cited by 10
Bone disease drug discovery: examining the interactions between osteoblast and osteoclast
Sun, S. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.2.239 · Cited by 9
Estrogen, Bone Homeostasis, and Osteoporosis
Riggs, B. L., Khosla, S., & Melton, L. J. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50042-2 · Cited by 13
Role of denosumab in breast cancer
Bartsch, R., & Steger, G. G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903146877 · Cited by 10
New Insights Into the Genetics of Autoimmune Myasthenia Gravis: An Evolving Story
Lisak, R. P., & Barcellos, L. F. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4493 · Cited by 9
Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate
Tsai, J. N., Zhu, Y., Foley, K., Lee, H., Burnett‐Bowie, S. M., Neer, R. M., & Leder, B. Z. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1541 · Cited by 8
Landi, L., Leali, P. T., Barbato, L., Carrassi, A., Discepoli, N., Muti, P. C., Oteri, G., Rigoni, M., Romanini, E., Ruggiero, C., et al. (2023) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-023-00713-7 · Cited by 12
Innovations thérapeutiques dans l’ostéoporose (anticorps antisclérostine et denosumab)
Quemerais, M. A., Kerlan, V., & Chabre, O. (2011) · Annales d Endocrinologie · doi:10.1016/s0003-4266(11)70005-1 · Cited by 12
Osteoporosis: non-hormonal treatment
Rizzoli, R. (2007) · Climacteric · doi:10.1080/13697130701600815 · Cited by 11
Bayer, C., Beckmann, M. W., & Fasching, P. A. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000333 · Cited by 8
Newer therapies in osteoporosis
Kanakamani, J., & Tandon, N. (2008) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(10)60141-0 · Cited by 8
Future Developments in Osteoporosis Therapy
Ng, K. W. (2009) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153009789839192 · Cited by 10
Norian, J. M., Zeitlian, G., Adel, G., Freeman, R. G., Santoro, N. F., & Pal, L. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.11.089 · Cited by 8
Cavalli, L., & Brandi, M. L. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.24 · Cited by 8
Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency
Daga, N., & Joseph, F. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-234508 · Cited by 9
Bone metabolism during long-term treatment with imatinib
O’Sullivan, S., Horne, A. M., Wattie, D. J., Porteous, F., Gamble, G. D., Browett, P., & Grey, A. B. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.760734 · Cited by 8
Treatment of Postmenopausal Osteoporosis
Gupta, G., & Aronow, W. S. (2007) · Comprehensive Therapy · doi:10.1007/s12019-007-0017-x · Cited by 9
Miller, K., Stenzl, A., & TOMBAL, B. F. (2009) · European Urology Supplements · doi:10.1016/j.eursup.2009.07.001 · Cited by 8
Bustamante-Gomez, C., Fu, Q., Goellner, J. J., Thostenson, J. D., Reyes-Pardo, H., & O’Brien, C. A. (2025) · Bone · doi:10.1016/j.bone.2025.117567 · Cited by 7
Ruixo, J. J. P., Zheng, J., & Mandema, J. W. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.228 · Cited by 7
Rank ligand as a target in musculoskeletal neoplasms
Cote, G. M. (2015) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-015-9310-y · Cited by 8
An Office-Based Approach to the Diagnosis and Management of Osteonecrosis
Ruggiero, S. L. (2013) · Atlas of the Oral and Maxillofacial Surgery Clinics · doi:10.1016/j.cxom.2013.05.004 · Cited by 7
Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma
Boyd, K. D., Davies, F. E., & Morgan, G. J. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_8 · Cited by 7
Hu, Y., Chines, A. A., Shi, Y., Seeman, E., & Guo, X.-D. E. (2021) · Bone · doi:10.1016/j.bone.2021.116187 · Cited by 7
Pharmacologic Management of Osteoporosis
Aynardi, M. C., & Ilyas, A. M. (2013) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2012.11.023 · Cited by 10
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
Morgans, A. K., & Smith, M. R. (2011) · Journal of Osteoporosis · doi:10.4061/2011/941310 · Cited by 7
Denosumab for the Treatment of Postmenopausal Osteoporosis
Lewiecki, E. M. (2009) · Women s Health · doi:10.2217/17455057.5.1.15 · Cited by 7
Self-citationDiagnóstico del hiperparatiroidismo primario
Gómez, M. D., HOZ-GUERRA, S. D. L., Duque, M. G., VEGA-BLANCO, M., & BLANCO-URBANEJA, I. (2019) · Revista ORL · doi:10.14201/orl.21428 · Cited by 7
Wotring, V. E. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9889-0_27 · Cited by 9
Doggrell, S. A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.4.663 · Cited by 7
Terasaki, M., Terasaki, Y., Yoneyama, K., Kuwahara, N., Wakamatsu, K., Nagahama, K., Kunugi, S., Takeshita, T., & Shimizu, A. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.04.018 · Cited by 8
Gonzales, C. B., Young, V., Ketchum, N. S., Bone, J., Oates, T. W., & Mungia, R. (2015) · PubMed · Cited by 13
Bleeding disorders and reduced bone density
Mansouritorghabeh, H., & Rezaieyazdi, Z. (2010) · Rheumatology International · doi:10.1007/s00296-010-1534-y · Cited by 7
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., & Delmas, P. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50065-3 · Cited by 11
Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate
Mei, Y., Cai, S., Jiang, Y., Tian, Y., Shen, L., Gu, J., Wang, C., Zhang, Z., & Zhang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1445093 · Cited by 6
Missed opportunities for osteoporosis management in older patients: a literature review
Manek, N. (2010) · Primary Health Care Research & Development · doi:10.1017/s1463423609990429 · Cited by 6
Iwamoto, N., Sato, S., Furukawa, K., Michitsuji, T., Shiraishi, K., Watanabe, K., Chiba, K., Osaki, M., & Kawakami, A. (2024) · Modern Rheumatology · doi:10.1093/mr/roae002 · Cited by 7
Maldonado-Gonzales, E., & Pietschmann, P. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0812-3 · Cited by 7
Bogado, C. E., Zanchetta, M. B., Boailchuk, J. A., Massari, F., & Zanchetta, J. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0040-1 · Cited by 6
Fujii, T., Ishikawa, M., Kubo, A., & Tanaka, Y. (2015) · Bone · doi:10.1016/j.bone.2015.08.016 · Cited by 6
Denosumab and bisphosphonates: Rivals or potential “partners”? A “hybrid” molecule hypothesis
Anastasilakis, A. D., Pοlyzos, S. A., Anastasilakis, C. D., Toulis, K. A., & Makras, P. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.03.039 · Cited by 6
Graduate Student Literature Review: The milk behind the mustache: A review of milk and bone biology
Batty, B., & Bionaz, M. (2019) · Journal of Dairy Science · doi:10.3168/jds.2019-16421 · Cited by 7
Structure of a DNA G-Quadruplex Related to Osteoporosis with a G-A Bulge Forming a Pseudo-loop
Živković, M. L., Rozman, J., & Plavec, J. (2020) · Molecules · doi:10.3390/molecules25204867 · Cited by 6
Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs
del Real, Á., Ciordia, S., Sañudo, C., García‐Ibarbia, C., Roa‐Bautista, A., Ocejo‐Viñals, J. G., Corrales, F. J., & Riancho, J. A. (2022) · Metabolites · doi:10.3390/metabo12050399 · Cited by 6
Niu, S., Chen, M., Yan, D., Liu, X., Guo, S., Ou, L., Fan, H., Lv, J., Wang, Q., Dong, W., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893166 · Cited by 7
Giant cell tumor of the humeral head treated by denosumab: Implication to shoulder surgeons
Leung, K. H., Lam, A. Y.-L., Ho, K. W. Y., & Shek, T. W. (2015) · International Journal of Shoulder Surgery · doi:10.4103/0973-6042.167956 · Cited by 6
Rhodes, S. D., Yang, H., Dong, R., Menon, K., He, Y., Li, Z., Shi, C., Staser, K. W., Jiang, L., Wu, X., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2538 · Cited by 7
YILMAZ, V. T., Özdem, S., Dönmez, L., Çetinkaya, R., Süleymanlar, G., & ERSOY, F. F. (2015) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2015.93 · Cited by 6
Cheng, B., & Chen, Y. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000178 · Cited by 6
Marocco, C., Zimatore, G., Mocini, E., Fornari, R., Iolascon, G., Gallotta, M. C., Bimonte, V. M., Baldari, C., Lenzi, A., & Migliaccio, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041728 · Cited by 6
Lane, N. E. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10092-0 · Cited by 7
Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis
Wimalawansa, S. J. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1202111 · Cited by 6
Targeting Osteoporosis and Rheumatoid Arthritis by Active Vaccination Against RANKL
Spohn, G., & Bachmann, M. F. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72009-8_17 · Cited by 7
Yasuda, H. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.153.11 · Cited by 6
Denosumab for the treatment of osteoporosis: A systematic literature review
Silva-Fernández, L., Rosario, M. P., Martínez-López, J. A., Carmona, L., & Loza, E. (2013) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2012.06.020 · Cited by 6
Long dosing intervals in the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x233278 · Cited by 7
Self-citation
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.